This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Why Amgen (AMGN) Could Beat Earnings Estimates Again
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BeiGene (BGNE) Up on Label Expansion of Tislelizumab in China
by Zacks Equity Research
BeiGene (BGNE) gains following the approval of tislelizumab for the lucrative indication of advanced squamous non-small cell lung cancer in China.
Esperion (ESPR) Reports Q4 Preliminary Results, Stock Down
by Zacks Equity Research
Esperion (ESPR) reports fourth-quarter preliminary results and provides guidance for operating expense in 2021. The company in-licenses oral PCSK9 inhibitor program.
Stock Market News for Jan 11, 2021
by Zacks Equity Research
Benchmarks hit fresh record highs on Friday as President-elect Joe Biden promised new fiscal aid following a weak December jobs data.
AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Disease Studies
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi achieves improvements in clinical remission and endoscopic response in phase III studies in moderate to severe Crohn's disease patients.
Radius (RDUS) to Acquire Rights for Cannabidiol Oral Solution
by Zacks Equity Research
Radius (RDUS) is set to acquire the global development and commercialization rights of Benuvia Therapeutics' synthetic cannabidiol oral solution for utilization in multiple endocrine and metabolic orphan diseases.
AbbVie's (ABBV) Skyrizi Succeeds in Psoriatic Arthritis Studies
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi achieves improvements in disease activity across joint and skin symptoms in phase III studies in active psoriatic arthritis.
Radius (RDUS) Inks Deal for Tymlos in Canada With Paladin Labs
by Zacks Equity Research
Radius (RDUS) signs an agreement with Paladin Labs, wherein the latter will now be responsible for all commercial activities related to Tymlos and abaloparatide-TD in Canada.
Top Analyst Reports for Microsoft, Procter & Gamble & QUALCOMM
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Procter & Gamble (PG), and QUALCOMM (QCOM).
Wall Street Stories That Hit Headlines in 2020
by Sweta Killa
With super-easy policies and vaccination, small-cap stocks like Liquidity Services (LQDT) and cyclical stocks like Nexstar Media (NXST), Deere & Company (DE) and BHP Billiton (BBL) are expected to benefit the most.
Aprea (APRE) Plunges as Late-Stage MDS Study Fails to Meet Goal
by Zacks Equity Research
Aprea (APRE) down as late-stage study on lead candidate, eprenetapopt, combined with azacitidine (AZA) versus AZA alone in TP53 mutant myelodysplastic syndromes (MDS) fails.
Biotech Stock Roundup: PFE/BNTX Vaccine Authorized in Europe, Updates From AMGN, & More
by Zacks Equity Research
Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) continue to take centerstage in the biotech sector.
Amgen/AstraZeneca's Asthma Drug Misses Phase III Study Goal
by Zacks Equity Research
Amgen (AMGN) and AstraZeneca (AZN) plan to file regulatory applications for tezepelumab next year.
Stock Market News for Dec 23, 2020
by Zacks Equity Research
Benchmarks closed mixed on Tuesday as investors remained concerned about rising coronavirus cases in America and Europe despite a vaccine rollout in progress and additional stimulus package.
Amgen (AMGN) Files for KRAS Inhibitor for Lung Cancer in Europe
by Zacks Equity Research
The regulatory filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which shows that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.
Merck (MRK) Gets FDA's Priority Review for Another Keytruda sBLA
by Zacks Equity Research
The FDA accepts Merck's (MRK) sBLA for Keytruda combo for first-line metastatic esophageal and gastroesophageal junction cancer, under a priority review. The FDA's verdict is awaited on Apr 13, 2021.
Amgen (AMGN) Submits NDA for KRAS Inhibitor for Lung Cancer
by Zacks Equity Research
The NDA filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which showed that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.
AbbVie's (ABBV) Rinvoq Gets CHMP Nod for Two New Indications
by Zacks Equity Research
AbbVie (ABBV) gets positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rinvoq for treating active psoriatic arthritis and active ankylosing spondylitis.
Merck (MRK) Keytruda Gets CHMP Nod for First-Line Colon Cancer
by Zacks Equity Research
Merck's (MRK) regulatory application seeking label expansion of Keytruda as first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer gets positive CHMP opinion.
Amgen (AMGN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $227.40 in the latest trading session, marking a -0.33% move from the prior day.
AbbVie's (ABBV) Rinvoq Meets Goal in Ulcerative Colitis Study
by Zacks Equity Research
AbbVie's (ABBV) phase III U-ACHIEVE study evaluating Rinvoq for treating patients with moderate to severe ulcerative colitis achieves the primary goal. The study also met all secondary endpoints.
Biotech Stock Roundup: ASH Data in Focus, CRIS, BCRX Surge & More Pipeline News
by Zacks Equity Research
Data readouts at ASH take centerstage in the biotech sector as Fate (FATE) and CRISPR (CRSP) among others provide key updates.
Amgen's (AMGN) KRAS Inhibitor Gets Breakthrough Tag for NSCLC
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy status on Amgen's (AMGN) KRAS inhibitor, sotorasib, for treating patients with advanced/metastatic non-small-cell lung cancer with KRAS G12C mutation.
Top Stock Reports for Facebook, Netflix & AbbVie
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook, Inc. (FB), Netflix, Inc. (NFLX) and AbbVie Inc. (ABBV).
FibroGen's (FGEN) Evrenzo Approved in Japan for Another Indication
by Zacks Equity Research
FibroGen's (FGEN) Evrenzo (roxadustat) wins second approval in Japan for treating anemia caused by chronic kidney disease in non-dialysis-dependent patients.